# Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
Canonical URL: https://biopharmsignal.com/news/CORT/corcept-to-resubmit-its-new-drug-application-for-relacorilant-as-a-treatment-for-patients-with-cushing-s-syndrome
Ticker: CORT
Company: Corcept
Source: Corcept
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.corcept.com
## Summary

REDWOOD CITY, Calif. --(BUSINESS WIRE)--May 27, 2026-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the

## Article Body
REDWOOD CITY, Calif. --(BUSINESS WIRE)--May 27, 2026-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the
## Recent Company News
- 2026-06-25 13:46 EST — [Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome](https://biopharmsignal.com/news/CORT/corcept-resubmits-new-drug-application-for-relacorilant-as-a-treatment-for-patients-with-cushing-s-syndrome) — Source: Corcept
- 2026-06-25 13:46 EST — [Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®](https://biopharmsignal.com/news/CORT/corcept-presents-new-data-at-ada-improved-outcomes-in-patients-receiving-a-glp-1-with-difficult-to-control-type-2-diabetes-and-hypercortisolism-treated-with-korlymr) — Source: Corcept
- 2026-06-25 13:46 EST — [Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure](https://biopharmsignal.com/news/CORT/corcept-presents-new-data-at-asco-2026-lifyorlitm-overall-survival-across-all-subgroups-of-patients-with-platinum-resistant-ovarian-cancer-including-those-with-recent-taxane-exposure) — Source: Corcept
- 2026-06-25 13:46 EST — [Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome](https://biopharmsignal.com/news/CORT/corcept-to-resubmit-its-new-drug-application-for-relacorilant-as-a-treatment-for-patients-with-cushing-s-syndrome) — Source: Corcept
- 2026-06-25 13:46 EST — [Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals](https://biopharmsignal.com/news/CORT/corcept-provides-update-on-patent-dispute-with-teva-pharmaceuticals) — Source: Corcept
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)